Join our daily newsletter At The Bell to receive exclusive market insights
- Cancer treatment company Prescient Therapeutics (PTX) is teaming up with world-renowned Peter MacCallum Cancer Centre to develop new cell therapy technologies
- The program will produce technologies that can complement the company’s existing CAR-T system
- CAR-T is a type of cellular therapy that reprograms the immune cells of cancer patients to recognise and destroy cancerous cells
- Under the agreement, Prescient will own resultant intellectual property from the program, which will be led by Peter Mac’s Professor Phil Darcy
- Despite this positive news, Prescient is down 1.67 per cent on the market this afternoon and is trading for 5.9 cents per share
Cancer treatment company Prescient Therapeutics (PTX) is teaming up with Peter MacCallum Cancer Centre to develop new cell therapy technologies.
The company says Peter Mac is an internationally recognised clinical leader in the new oncology treatment space.
Under the contract, Prescient will own resultant intellectual property (IP) from the research program, which will be led by Peter Mac’s Professor Phil Darcy.
The program will look to produce technologies that can complement the existing CAR-T approaches.
CAR-T is a type of cellular therapy that reprograms the immune cells of cancer patients to recognise and destroy cancerous cells.
The research program is an important addition to Prescient’s Cell Therapy Enhancements (CTE) programs.
“CAR-T therapy has shown strong therapeutic activity in certain haematological malignancies, however, the effects in solid cancers have been poor to date,” Phil said.
“The approach we are exploring with Prescient may reprogram the tumour microenvironment that results in significantly enhancing CAR T cell anti-tumour activity,” he added.
Prescient CEO Steven Yatomi-Clarke said it’s a race against time for many cancer patients, so joining the world leaders at Peter Mac will help enhance its treatments.
“Prescient is the only ASX-listed company developing CAR-T programs and this
is an important strategic initiative to complement our programs in cell therapy enhancements,” he said.
“We look forward to working closely with Peter Mac as we employ our knowledge of targeted therapies and growing standing in cellular therapies to generate technologies that will be relevant for the CAR-T field,” he added.
Despite this positive news, Prescient is down 1.67 per cent on the market this afternoon and is trading for 5.9 cents per share at 12:28 pm AEST.
